Antibody data
- Antibody Data
- Antigen structure
- References [35]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF347 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal TRAILR1/TNFRSF10A Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TRAIL R1/TNFRSF10A in direct ELISAs and Western blots. In Western blots, approximately 10% cross-reactivity with recombinant human (rh) TRAIL R2 is observed and less than 1% cross-reactivity with rhTRAIL R3 and rhTRAIL R4 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism.
Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.
Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells.
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Serrano-Saenz S, Palacios C, Delgado-Bellido D, López-Jiménez L, Garcia-Diaz A, Soto-Serrano Y, Casal JI, Bartolomé RA, Fernández-Luna JL, López-Rivas A, Oliver FJ
Cell death & disease 2019 Jan 18;10(2):51
Cell death & disease 2019 Jan 18;10(2):51
Downregulation of DcR3 sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Liang C, Xu Y, Li G, Zhao T, Xia F, Li G, Zhang D, Wu J
OncoTargets and therapy 2017;10:417-428
OncoTargets and therapy 2017;10:417-428
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V, Zysk A, DeNichilo M, Zinonos I, Hay S, Panagopoulos V, Shoubridge A, Difelice C, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino ACW, Evdokiou A
Cancer medicine 2017 Sep;6(9):2164-2176
Cancer medicine 2017 Sep;6(9):2164-2176
Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
Shlyakhtina Y, Pavet V, Gronemeyer H
Cell death & disease 2017 Aug 31;8(8):e3025
Cell death & disease 2017 Aug 31;8(8):e3025
Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).
Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, Ponomarev V, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A
Anticancer research 2014 Dec;34(12):7007-20
Anticancer research 2014 Dec;34(12):7007-20
Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
Elias A, Siegelin MD, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5457-65
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Sep 1;15(17):5457-65
Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells.
Park SJ, Sohn HY, Yoon J, Park SI
Cellular signalling 2009 Oct;21(10):1495-503
Cellular signalling 2009 Oct;21(10):1495-503
Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
Siegelin MD, Gaiser T, Habel A, Siegelin Y
Cancer letters 2009 Oct 8;283(2):230-8
Cancer letters 2009 Oct 8;283(2):230-8
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ, Kim MJ, Kim HB, Sohn HY, Bae JH, Kang CD, Kim SH
Biochemical pharmacology 2009 Apr 15;77(8):1328-36
Biochemical pharmacology 2009 Apr 15;77(8):1328-36
TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5.
Wu CH, Kao CH, Safa AR
Human gene therapy 2008 Jul;19(7):731-43
Human gene therapy 2008 Jul;19(7):731-43
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S, Choi KS
Cancer research 2008 Jan 1;68(1):266-75
Cancer research 2008 Jan 1;68(1):266-75
Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M
International journal of oncology 2008 Aug;33(2):381-8
International journal of oncology 2008 Aug;33(2):381-8
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Zopf S, Neureiter D, Bouralexis S, Abt T, Glaser KB, Okamoto K, Ganslmayer M, Hahn EG, Herold C, Ocker M
International journal of oncology 2007 Dec;31(6):1391-402
International journal of oncology 2007 Dec;31(6):1391-402
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R, Kumar SR, Sinha UK, Crowe DL, Krasnoperov V, Reddy RK, Zozulya S, Singh J, Xia G, Broek D, Schönthal AH, Gill PS
International journal of cancer 2006 Sep 15;119(6):1236-48
International journal of cancer 2006 Sep 15;119(6):1236-48
Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3.
Lane D, Côté M, Grondin R, Couture MC, Piché A
Molecular cancer therapeutics 2006 Mar;5(3):509-21
Molecular cancer therapeutics 2006 Mar;5(3):509-21
P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Biochemical pharmacology 2006 Jul 28;72(3):293-307
Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Roux S, Lambert-Comeau P, Saint-Pierre C, Lépine M, Sawan B, Parent JL
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Biochemical and biophysical research communications 2005 Jul 22;333(1):42-50
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt.
Morel J, Audo R, Hahne M, Combe B
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
The Journal of biological chemistry 2005 Apr 22;280(16):15709-18
Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death.
Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A, Colombo A, Parati E, Peschle C, De Maria R
The Journal of experimental medicine 2004 Nov 15;200(10):1257-66
The Journal of experimental medicine 2004 Nov 15;200(10):1257-66
TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia.
Ryan LA, Peng H, Erichsen DA, Huang Y, Persidsky Y, Zhou Y, Gendelman HE, Zheng J
Journal of neuroimmunology 2004 Mar;148(1-2):127-39
Journal of neuroimmunology 2004 Mar;148(1-2):127-39
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Ruiz de Almodóvar C, Ruiz-Ruiz C, Rodríguez A, Ortiz-Ferrón G, Redondo JM, López-Rivas A
The Journal of biological chemistry 2004 Feb 6;279(6):4093-101
The Journal of biological chemistry 2004 Feb 6;279(6):4093-101
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).
Chopin V, Slomianny C, Hondermarck H, Le Bourhis X
Experimental cell research 2004 Aug 15;298(2):560-73
Experimental cell research 2004 Aug 15;298(2):560-73
Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.
Nakajima H, Yanase N, Oshima K, Sasame A, Hara T, Fukazawa S, Takata R, Hata K, Mukai K, Yamashina A, Mizuguchi J
Japanese heart journal 2003 Nov;44(6):833-44
Japanese heart journal 2003 Nov;44(6):833-44
Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction.
Nakajima H, Yanase N, Oshima K, Sasame A, Hara T, Fukazawa S, Takata R, Hata K, Mukai K, Yamashina A, Mizuguchi J
Japanese heart journal 2003 Nov;44(6):833-44
Japanese heart journal 2003 Nov;44(6):833-44
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Cancer biology & therapy 2003 May-Jun;2(3):283-90
An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Cancer biology & therapy 2003 May-Jun;2(3):283-90
Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, Miyazoe S, Nakagawa Y, Ishikawa H, Hamasaki K, Nakata K, Ishii N, Eguchi K
Oncogene 2003 Mar 20;22(11):1653-62
Oncogene 2003 Mar 20;22(11):1653-62
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines.
Mouzakiti A, Packham G
British journal of haematology 2003 Jul;122(1):61-9
British journal of haematology 2003 Jul;122(1):61-9
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
Journal of leukocyte biology 2003 Aug;74(2):223-32
Journal of leukocyte biology 2003 Aug;74(2):223-32
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells.
Secchiero P, Milani D, Gonelli A, Melloni E, Campioni D, Gibellini D, Capitani S, Zauli G
Journal of leukocyte biology 2003 Aug;74(2):223-32
Journal of leukocyte biology 2003 Aug;74(2):223-32
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells.
Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P
Circulation research 2003 Apr 18;92(7):732-40
Circulation research 2003 Apr 18;92(7):732-40
Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells.
Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr
Cell death and differentiation 2002 Mar;9(3):274-86
Cell death and differentiation 2002 Mar;9(3):274-86
Apoptosis-mediating receptor-ligand systems in human retinal pigment epithelial cells.
Hueber A, Aduckathil S, Kociok N, Welsandt G, Dinslage S, Kirchhof B, Esser PJ
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2002 Jul;240(7):551-6
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2002 Jul;240(7):551-6
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
Oncogene 2002 Aug 22;21(37):5673-83
Oncogene 2002 Aug 22;21(37):5673-83
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Detection of Human TRAIL R1/TNFRSF10A by Western Blot. Western blot shows lysates of TF-1 human erythroleukemic cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R1/TNFRSF10A at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- TRAIL R1/TNFRSF10A in Human Brain. TRAIL R1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human brain using Goat Anti-Human TRAIL R1/TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in neurons. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- TRAIL R1/TNFRSF10A Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R1/TNFRSF10A Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (Catalog # 347-DR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R1/TNFRSF10A Fc Chimera (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R1/ TNFRSF10A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF347). The ND50 is typically 0.02-0.055 µg/mL.